Security key
87961M105
Telix Pharmaceuticals Ltd - Ordinary Shares (TLX)
CUSIP: 87961M105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary Shares
- Total 13F shares
- 188,803
- Total 13F value
- $2,176,898
- Share change
- +185,840
- SEC-reported price per share
- $11.53
- Number of holders
- 9
- Value change
- +$2,142,734
- Number of buys
- 7
- Number of sells
- 1
- Shares outstanding
- 334,705,968
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
9
Top holders
9
TLX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Telix Pharmaceuticals Ltd SEC filings
Telix Pharmaceuticals Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87961M105
Recent filing periods:
Ownership snapshot
Top reported holders of TLX - Telix Pharmaceuticals Ltd - Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Behrenbruch Christian
Disclosed value leader
Behrenbruch Christian
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 7%
13D/G row: Behrenbruch Christian
Showing 1-6 of 15 holder rows.
Quick read
Behrenbruch Christian leads the comparable SEC ownership view at 7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Behrenbruch Christian's linked filing trail.
Comparable ownership
Top 5
Behrenbruch Christian
7%
Kluge Andreas
6.8%
Mr. Mark Nelson
1.1%
Ms. Jann Skinner
0.18%
David Norman Cade
0.11%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Behrenbruch Christian |
13D/G
3/4/5
MD & Group CEO, Director
|
7%
|
$404,991,544
23,329,006 shares
|
$0 | 12 Nov 2024 |
| Kluge Andreas |
13D/G
|
6.8%
|
$393,638,000
22,675,000 shares
|
$0 | 12 Nov 2024 |
| Mr. Mark Nelson |
3/4/5
Director
|
1.1%
|
$27,179,337
3,628,750 shares
|
— | 18 Mar 2026 |
| Ms. Jann Skinner |
3/4/5
Director
|
0.18%
|
$4,474,400
595,000 shares
|
— | 18 Mar 2026 |
| David Norman Cade |
3/4/5
Group Chief Medical Officer
|
0.11%
|
$2,794,766
373,133 shares
|
— | 18 Mar 2026 |
| Darren Charlton Smith |
3/4/5
Group Chief Financial Officer
|
0%
|
$89,288
11,921 shares
|
— | 29 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
188,803
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
38
Q2 2026 holders
9
Holder diff
-29
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend